LOGC Logicbio Therapeutics, Inc.

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 that is been developed for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. LogicBio Therapeutics, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/19/2018
Outstanding shares:  32,956,794
Average volume:  90,028
Market cap:   $99,199,950
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    54142F102
ISIN:        US54142F1021
Valuation   (See tab for details)
PE ratio:   -2.65
PB ratio:   2.59
PS ratio:   25.27
Return on equity:   -97.68%
Net income %:   -964.74%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy